Cardio Diagnostics Holdings, Inc. carries a market capitalization of 3.46M, placing it among publicly traded companies globally. Its enterprise value stands at -2.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.46M |
| Enterprise Value | -2.42M |
Cardio Diagnostics Holdings, Inc. currently has 2.96M shares outstanding.
| Shares Outstanding | 2.96M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
The price-to-sales ratio is 248.69, and the price-to-book ratio stands at -0.13.
| PE Ratio | N/A |
| PS Ratio | 248.69 |
| PB Ratio | -0.13 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | -0.76 |
| P/OCF Ratio | -0.70 |
| EV / Sales | 74.80 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Cardio Diagnostics Holdings, Inc. maintains a current ratio of 15.76, meaning it holds 15.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.99, indicating elevated leverage, while an interest coverage ratio of -462.83 demonstrates limited ability to service its debt obligations.
| Current Ratio | 15.76 |
| Quick Ratio | 14.41 |
| Debt / Equity | 5.99 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | -462.83 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -60.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Cardio Diagnostics Holdings, Inc.'s stock has declined approximately -62.63982% over the past 52 weeks. The 50-day moving average sits at 1.87, while the 200-day moving average is 2.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | -62.63982% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 2.65 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Cardio Diagnostics Holdings, Inc. generated 16,565.00 in revenue and converted that into -6.65M in net income, yielding earnings per share of -3.15. EBITDA reached -6.27M, while operating income came in at -6.64M.
| Revenue | 16,565.00 |
| Gross Profit | N/A |
| Operating Income | -6.64M |
| Pretax Income | -6.65M |
| Net Income | -6.65M |
| EBITDA | -6.27M |
| EBIT | -6.64M |
| Earnings Per Share (EPS) | -3.15 |
Cardio Diagnostics Holdings, Inc. holds 7.08M in cash and equivalents against 533,002.00 in total debt, resulting in a net debt position of -6.91M. Total book value stands at -31.04M, with working capital of 7.25M providing operational flexibility.
| Cash & Cash Equivalents | 7.08M |
| Total Debt | 533,002.00 |
| Net Debt | -6.91M |
| Equity (Book Value) | -31.04M |
| Book Value Per Share | -14.69 |
| Working Capital | 7.25M |
Cardio Diagnostics Holdings, Inc. produced -5.89M in operating cash flow over the past twelve months. After subtracting -435,591.00 in capital expenditures, free cash flow totaled -6.32M - equivalent to -2.99 per share.
| Operating Cash Flow | -5.89M |
| Capital Expenditures | -435,591.00 |
| Free Cash Flow | -6.32M |
| FCF Per Share | -2.99 |
Cardio Diagnostics Holdings, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -40,074.58 and net profit margin of -40,152.50 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -40,074.58 |
| Pretax Margin | -40,152.50 |
| Profit Margin | -40,152.50 |
| EBITDA Margin | -37,856.29 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -90.13 |
| FCF Yield | -132.38 |
Cardio Diagnostics Holdings, Inc.'s most recent stock split took place on May 13, 2025 with a 30:1 split ratio.
| Last Split Date | 5/13/2025 |
| Split Ratio | 30:1 |
Cardio Diagnostics Holdings, Inc. posts an Altman Z-Score of -2.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.80 |